A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

To evaluate the efficacy of NYX-2925 versus placebo in treating the neuropathic pain associated with diabetic peripheral neuropathy.

开始日期2019-11-12

申办/合作机构

Aptinyx, Inc.

[+1]

NCT03249103

/ Completed临床2期

A Phase 2, Single-Blind, Exploratory, Placebo-controlled, Pilot Study to Assess the Efficacy and Safety of Daily Oral NYX-2925 in Subjects With Fibromyalgia

The primary objective is to determine whether daily dosing with NYX-2925 changes markers of central pain processing in subjects with fibromyalgia by evaluating changes in evoked pain, and visual stimulation, functional magnetic resonance imaging (fMRI), resting state function connectivity magnetic resonance imaging (rs-fcMRI) and proton magnetic resonance spectroscopy (H-MRS) in fibromyalgia subjects on active drug versus placebo.

开始日期2017-08-14

申办/合作机构

Aptinyx, Inc.

[+1]

100 项与 NYX-2925 相关的临床结果

登录后查看更多信息

100 项与 NYX-2925 相关的转化医学

登录后查看更多信息

100 项与 NYX-2925 相关的专利（医药）

登录后查看更多信息

项与 NYX-2925 相关的文献（医药）

2026-01-01·ACTA PHARMACOLOGICA SINICA

New advances in small molecule drugs targeting NMDA receptors

Review

作者: Zeng, Yue ; Zhu, Qian-Wen ; Wang, Hai-Ying ; Gao, Zhao-Bing ; Qu, Zhi-Yan ; Zhou, Yu

N-methyl-D-aspartate (NMDA) receptors are glutamate-gated ion channels that are ubiquitously expressed throughout the central nervous system (CNS) and serve as crucial mediators of neural development and synaptic plasticity. Dysregulation of NMDA receptor activity has been implicated in a wide spectrum of neurological and psychiatric disorders. In recent years, substantial progress has been made in the clinical development of small-molecule modulators targeting NMDA receptors. In this review, we summarize recent advances in this rapidly evolving field. Among various therapeutic indications, depression has emerged as an especially active area of investigation, with mechanistically diverse compounds ranging from broad-spectrum channel blockers (ketamine, dextromethorphan, esmethadone) to glycine site modulators (rapastinel, 4-chlorokynurenine, D-cycloserine) and allosteric modulators (apimostinel, zelquistinel), progressing through clinical pipelines. Beyond depression, NMDA receptor-targeted drug discovery is also advancing in other challenging CNS disorders, including neurodegenerative diseases (salzanemdor, NYX-458), pain (NYX-2925), epilepsy (radiprodil), and stroke (nelonemdaz, NP10679). Collectively, these developments reflect the maturation of NMDA receptor pharmacology and reaffirm the broad therapeutic potential of NMDA receptor modulation, while highlighting promising directions for future drug discovery.

2021-09-17·Current medicinal chemistry2区 · 医学

New Small-molecule Analgesics

2区 · 医学

Review

作者: Laev, Sergey S. ; Salakhutdinov, Nariman F.

Pain is a symptom of ninety percent of human diseases, and pain management is a very important medicinal problem. Various modulators of the pain response have been detected, and analgesic effects are obtained by increasing inhibition or decreasing excitation in the nervous system. Various known analgesic drugs are commonly used to relieve the pain; however, this problem is still not fully resolved by currently available treatments. Available analgesic drugs (non-steroidal anti-inflammatory drugs, opioids and analgesic adjuvants) are not too effective and are severely limited by adverse effects, for example, opioid addiction. Therefore, developing effective pain management is a difficult but necessary task. Thus, there is an urgent need for further development of the design and synthesis of new analgesic agents. The aim of this review is to present recent progress in search of new small molecule analgesics. The structures and effects of new perspective analgesic agents (anti-inflammatory agents, opioid analgesics, adjuvant agents for pain management, and natural compounds) are presented and discussed. The review covers the literature published in 2015-2020 years and includes 173 references.

2021-03-01·Medicine in drug discovery

NYX-2925, A NOVEL, NON-OPIOID, SMALL-MOLECULE MODULATOR OF THE N-METHYL-d-ASPARTATE RECEPTOR (NMDAR), DEMONSTRATES POTENTIAL TO TREAT CHRONIC, SUPRASPINAL CENTRALIZED PAIN CONDITIONS

作者: Gajda, Jessica Marie ; Ghoreishi-Haack, Nayereh ; Morrison, Gladys ; Barth, Amanda Lynn ; Asiedu, Marina ; Dunning, Jacqueline Ann

Pain is both a sensory and emotional experience, which serves an adaptive purpose by protecting the body from prolonged and repeated tissue damage.However, the presence of chronic pain can transition to a maladaptive state leading to life-long suffering and is currently a health care burden due to limited effective pharmacotherapies.This review aims to describe the transition to a chronic pain state and the central changes (supraspinal) that occur to prolong the unpleasant feelings of pain.In addition to alterations in the periphery and spinal cord, regions in the brain involved in pain perception as well as executive functioning undergo changes in activity that reflect painful experiences from nonpainful stimuli.These pathol. changes to the nociceptive system are partly mediated by expression and activity patterns of N-methyl-D-aspartate receptors (NMDARs), which process and propagate excitatory transmission in response to glutamate release in the periphery, spinal cord, and brain and have an important role in learning and memory.Importantly, NMDARs have been implicated in the cellular mechanisms responsible for the maintenance of the centralized, chronic pain state within the brain.Here we present preclin. data describing the analgesic effects of NYX-2925, a novel NDMAR modulator in a variety of neuropathic pain rodent models.These data provide compelling evidence that targeting brain regions responsible for the affective and cognitive aspects of pain may alleviate chronic pain and serve as a novel mechanism to treat chronic pain conditions, including those refractory to current analgesics.

项与 NYX-2925 相关的新闻（医药）

2023-03-01

·药时代

3个临床试验全部输给安慰剂，是天灾还是人祸？

创新药BD高阶研讨会【上海站】！点击这里立刻报名！撰文| 菜一碟有这么一家Biotech，8年时间，只做一个靶点。基于这个靶点，这家Biotech铺出了3条管线，共4个适应症，还将这4个适应症都带到了2期临床，4个适应症分别为：糖尿病周围神经性疼痛(DPN)、纤维肌痛综合征(FM)、帕金森氏病认知障碍(PDD)、创伤后应激障碍(PTSD)。（都是CNS的天坑）可惜，如今这3条管线全部“扑街”（失败*2，自愿停止*1），除了关于PTSD的2期试验是自愿停止外，其他2期试验均败给了安慰剂。他就是Aptinyx（以下简称A司），一家专注于发现和开发治疗大脑和神经系统疾病的创新疗法的Biotech。A司的独到之处在于，他的所有候选产品都是NMDA受体调节剂。NMDA受体（N-甲基-D-天冬氨酸受体）是中枢神经系统发育的重要组成部分，其作用是控制突触可塑性，介导学习和记忆功能。如果NMDA受体被过度激活，会导致Ca2+过量流入神经元，引起细胞死亡，这种现象被称为兴奋毒性，而兴奋毒性又与神经退行性病变（中风、帕金森、老年痴呆等）有关。反之，当NMDA受体被阻断时，会改变突触间的信号传递，导致幻听、认知障碍、精神分裂等。那么理论上，只要合理控制NMDA受体的活性，便可治疗由此（NMDA受体过度激活/阻断）引发的一系列疾病。而A司的NMDA受体调节剂，是有选择性地激活某些亚型的NMDA受体的能力，而不是直接过度激活或阻断NMDA受体。减少其副作用，从而达到更温和的效果、更好的安全性和耐受性。既然理论上非常可行，又为何做起试验“一碰就碎”（干不过安慰剂）?先看试验。A司共有NYX-2925、NX783、NX458三条管线，以NYX-2925为例（A司最重要也最早的管线），NYX-2925做了两个适应症：糖尿病周围神经性疼痛(DPN)、纤维肌痛综合征(FM)。2016年，NYX-2925完成1期临床试验入组（入组人数84），同年获FDA授予的快速通道指定，2017年试验完成，结果积极。NYX-2925的1期试验是一项随机、双盲、安慰剂对照的剂量递增试验，旨在评估NYX-2925在健康志愿者中的安全性、耐受性和药代动力学。该试验共招募了84名志愿者，分为单次口服组和多次口服组，分别给予不同剂量的NYX-2925或安慰剂。1期结果显示，NYX-2925在所有剂量水平下均表现出良好的安全性和耐受性，没有出现严重不良事件或停药事件。NYX-2925还显示出与预期相符的药代动力学特征，具有快速吸收、高生物利用度和适中的半衰期。基于此项结果，A司快速推进NYX-2925(DPN)的2a试验。NYX-2925（DPN）的2a试验是一项随机、双盲、安慰剂对照、多中心的临床试验，共招募了300名DPN患者，分别给予10mg、50mg或200mg NYX-2925或安慰剂，每天一次，连续28天。2a试验的主要终点是评估NYX-2925对改善11点数值评分量表(NRS)上的平均每日最低疼痛强度 (ADLPI)的效果。2a试验结果显示，在总体患者群中，NYX-2925在50 mg剂量组达到了统计学和临床上显著改善ADLPI的效果，而10mg和200mg剂量组则未达到显著差异。A司在官方新闻稿里重点强调了，在DPN较重的患者群中(基线时NRS评分27)，NYX-2925在50 mg剂量组表现出更强的止痛效果，而其他两个剂量组也显示出趋势性改善此外，试验还发现NYX-2925具有良好的药代动力学特征和耐受性。这个结果看上去没什么毛病，50mg效果显著，唯一的缺陷就是没做出剂量相关性，但正是这个小缺陷暗示了后续所有临床试验的失败，具体请看全人群的临床数据。在全人群的疗效结果里，不仅没有做出剂量相关性，10mg剂量组的疗效还要弱于安慰剂。不过A司并没有把这个数据放在心上，在NYX-2925（DPN）的2a试验之后，便就50mg的剂量做了2b试验。NYX-2925（DPN）的2b试验主要针对晚期疼痛性DPN患者的一项随机、双盲、安慰剂对照的临床试验，共招募了229名患者，分别给予50 mg NYX-2925或安慰剂，每天一次，连续28天。2b试验的主要终点是评估NYX-2925对改善NRS上的ADLPI的效果。2b试验结果显示，在总体患者群中，NYX-2925末能达到主要终点(与安慰剂相比差异为0.24分;p=0.54)，也未能在任何次要终点上显示出显著改善。头铁的娃又去做了NYX-2925（纤维肌痛综合征），结果不出意外，惨遭失败。同样的事情还发生在NYX-458(帕金森适应症)的2期试验上。这样的失败到底是天灾还是人祸？如今（2022年2月27日），A司宣布要削减成本，寻找替代方案，主动暂停了还没出结果的NYX-783（PTSD）。也就是说，A司已经没有“回天”的机会了。至于管线中的NYX-783（阿片类药物使用障碍、OUD）仍处IND阶段，连同管线的2期都停了，不停它完全是因为A司没法停。2022年，美国国立卫生研究院（NIH）拨款560万美元，资助A司用于NYX-783（OUD）的开发。根据A司最新财报（2022年第三季度）：截至2022年9月30日，现金和现金等价物为6650万美元，2022年初还有1.061亿美元，3个月内研发费用为1000万美元。当时，A司预计还能撑到2024年，现在看来由于2023年2月NYX-783的失败，A司要提前收场了。再看二级市场，NYX-2925（DPN）的2a试验结果出来后，A司股价出现大跳水，从最高点30美元跳到5美元。后来A司又2次增发股票，让自己的股价再无波澜，一片坦途。如今A司股价不到0.2美元，总市值从9.7亿美元缩水至1327亿美元。A司在官网上的第一篇新闻稿中这样写道：“当我们结束Naurex（Naurex被收购后，A司从中剥离出来）故事的最后一章时，我们很高兴与Aptinyx重新开始......”8年过去，投资人和他们应该都不是很高兴。参考资料：1.Aptinyx官网2.FDA官网3.https://clinicaltrials.gov/ct2/results?cond=NYX-2925&draw=2&rank=4#rowId34.其他公开资料封面图来源：电影《破坏之王》推荐阅读3期疗效还没出，光有药代动力学结果，股价就大涨70%……辉瑞要收购Seagen？华尔街日报：正在谈判！问了CHATGPT亲兄弟「中国药企会面临哪些风险」虽然是车轱辘话，但好像很有道理……点击这里，报名创新药BD高阶研讨会【上海站】！

临床2期快速通道临床1期

2023-02-28

·MedCity News

Parkinson’s Trial Failure Signals a Likely End for CNS Biotech Aptinyx

Aptinyx’s approach of treating neurological disorders by targeting a key receptor in the brain has fallen short again, this time in Parkinson’s disease. With its third clinical trial failure in less than a year, the biotech said it will end the Parkinson’s program as well as a separate one in post-traumatic stress disorder. The drug candidate for Parkinson’s, NYX-458, was in testing as a potential treatment for mild cognitive impairment or mild dementia associated with that disease or a closely related neurological disorder called dementia with Lewy bodies. The once-daily pill was being evaluated in a 99-patient, placebo-controlled study. According to preliminary results released after Monday’s market close, the Aptinyx drug did not show clinically meaningful improvement as assessed using tests to evaluate function and cognition in Parkinson’s patients. “The results overall do not support further advancement of the development program by Aptinyx,” the company said in its announcement. Evanston, Illinois-based Aptinyx develops small molecule drugs that target and modulate N-methyl-D-asparate (NMDA) receptors. These receptors are important to normal function of the brain and central nervous system. Aptinyx’s drugs stem from its platform technology for discovering molecules that can modulate NMDA receptors. The Aptinyx technology has yielded drug candidates for chronic pain, Parkinson’s, and PTSD. Last April, Aptinyx reported that chronic pain drug NYX-2925 failed to distance itself from a placebo in a Phase 2 study enrolling patients with diabetic peripheral neuropathy. The company continued a mid-stage test assessing the drug in fibromyalgia. Last August, the chronic pain drug failed that study as well. After the Parkinson’s failure, Aptinyx isn’t waiting to see the results for drug candidate NYX-783 in PTSD. The company said it will terminate that study and analyze the data to determine its next steps for that program. Aptinyx also said it will implement cost-cutting measures and explore “strategic alternatives,” which could mean a sale of the company or its assets, or perhaps a merger with a privately held biotech looking for way to enter the public markets. Aptinyx’s drug discovery technology came from Naurex, a psychiatric drugmaker that was acquired by Allergan in 2015. That year, Aptinyx launched to develop its NMDA receptor-targeting drugs. The company went public in 2018, pricing its shares at $16 each and raising nearly $118 million. Shares of Aptinyx opened Tuesday at 20 cents apiece. Image: Dr_Microbe, Getty Images

临床2期

2023-02-28

·FierceBiotech

Aptinyx, reeling from series of setbacks, dumps dementia drug, stops PTSD trial after phase 2 flop

Aptinyx is yet to publicly disclose layoffs but said it will “undertake cost-cutting measures.” Serial clinical trial train wreck Aptinyx is at it again. After seeing a pain prospect flunk three clinical trials, the biotech has added Parkinson's disease and dementia to its list of failed indications—prompting it to stop work on its two clinical candidates, cut costs and seek strategic alternatives. Last year, the third midphase failure of NYX-2925 prompted Aptinyx to drop the pain program and switch its attention to a pair of other NMDA receptor positive allosteric modulators, NYX-458 and NYX-783. The delivery of data from a phase 2 clinical trial of NYX-458 has prompted the company to rethink its plans once again and sent its stock down 54% to 27 cents in premarket trading. The midphase study randomized 99 patients with mild cognitive impairment or mild dementia caused by Parkinson’s or Lewy body dementia to receive NYX-458 or placebo for 12 weeks. Aptinyx began the trial on the basis of evidence that the molecule boosts cognition by addressing glutamatergic dysregulation. Across a slate of efficacy endpoints, NYX-458 failed to deliver on the preclinical promise. Aptinyx is yet to share data from the trial but revealed the absence of clinically meaningful improvements. The efficacy endpoints included two evaluations of the patients’ everyday functions and a battery of computerized neurocognitive tests designed to assess cognition. The comprehensive failure led Aptinyx to drop plans for further development of NYX-458. The fallout has hit the rest of the business, with the biotech terminating an ongoing study of NYX-783 in post-traumatic stress disorder (PTSD) early. Aptinyx had expected to report phase 2b data in PTSD in the second half of the year. Now, the biotech will review the data generated on NYX-783 to date to inform the next steps while trying to conserve its cash and identify a way out of its current predicament. Aptinyx is yet to publicly disclose layoffs but said it will “undertake cost-cutting measures.” The biotech ended September with $67 million to its name.

临床2期

100 项与 NYX-2925 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
糖尿病周围神经性疼痛	临床2期	美国	Aptinyx, Inc.	2019-11-12
纤维肌痛	临床2期	美国	Aptinyx, Inc.	2017-08-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04147858 (CTgov)	临床2期	纤维肌痛	310	NYX-2925 (NYX-2925 50 mg)	憲範鹹壓淵鏇獵願醖範(齋構餘獵範廠鬱醖鏇繭) = 簾構遞蓋齋繭窪觸夢廠醖網獵憲鏇築齋製廠鹹 (簾蓋製糧繭鏇鹹製築願, 1.603) 更多	-	2023-04-28
				NYX-2925 (NYX-2925 100 mg)	憲範鹹壓淵鏇獵願醖範(齋構餘獵範廠鬱醖鏇繭) = 繭構願糧簾窪淵鹹齋觸醖網獵憲鏇築齋製廠鹹 (簾蓋製糧繭鏇鹹製築願, 1.983) 更多
NCT04146896 (CTgov)	临床2期	糖尿病周围神经性疼痛	228	NYX-2925 50 mg (NYX-2925)	窪廠壓選繭淵獵鬱簾艱(積餘製衊觸簾鑰築網鑰) = 築遞蓋鹽簾艱窪範憲齋範構襯簾淵餘顧淵願顧 (糧餘廠鏇夢願製襯鏇鹹, 1.821) 更多	-	2023-04-28
				Placebo (Placebo)	窪廠壓選繭淵獵鬱簾艱(積餘製衊觸簾鑰築網鑰) = 淵膚網鹹製鑰簾餘顧觸範構襯簾淵餘顧淵願顧 (糧餘廠鏇夢願製襯鏇鹹, 2.102) 更多
NCT03249103 (CTgov)	临床2期	纤维肌痛	22	Placebo+NYX-2925	願鹹積獵構鬱夢襯獵衊(廠膚廠齋範願醖夢糧願) = 糧構選醖夢窪齋壓選築夢獵餘憲製淵鹽鹹製廠 (餘鬱製鏇壓遞積鬱繭醖, 0.17796) 更多	-	2022-09-16
NCT04147858 (BusinessWire) 人工标引	临床2期	纤维肌痛	300	NYX-2925	網繭窪鏇窪壓積夢簾憲(鏇築蓋鏇夢築網餘齋觸) = NYX-2925 did not achieve the primary endpoint of the study 膚鹹構齋積製鹽積齋壓 (廠膚鏇醖壓鑰製鏇鏇夢 )	不佳	2022-08-12
				Placebo
NCT03219320 (DPN, CTgov)	临床2期	神经痛 \| 糖尿病周围神经病变	301	NYX-2925 (NYX-2925 200 mg QD)	繭衊窪艱鏇網積醖遞網(鏇鑰餘範築鹽選夢齋網) = 遞鏇衊膚鑰觸網願窪憲艱壓製築鏇衊蓋獵廠醖 (鑰壓蓋衊顧觸艱鏇願繭, 0.19) 更多	-	2020-06-09
				NYX-2025 (NYX-2025 50 mg QD)	繭衊窪艱鏇網積醖遞網(鏇鑰餘範築鹽選夢齋網) = 蓋艱選鏇鹽願壓遞廠醖艱壓製築鏇衊蓋獵廠醖 (鑰壓蓋衊顧觸艱鏇願繭, 0.19) 更多
NCT03249103 (GlobeNewswire) 人工标引	临床2期	纤维肌痛	23	NYX-2925	觸淵選鏇鏇鹽簾積鹽網(獵壓齋範鑰簾憲願鹽蓋) = 壓觸網襯憲膚獵鹽艱願範廠蓋顧鏇淵觸鏇鏇糧 (網憲製壓醖鏇窪艱餘齋 ) 更多	积极	2019-06-10
				Placebo	觸淵選鏇鏇鹽簾積鹽網(獵壓齋範鑰簾憲願鹽蓋) = 憲構鹽製窪醖鹽鏇憲壓範廠蓋顧鏇淵觸鏇鏇糧 (網憲製壓醖鏇窪艱餘齋 ) 更多
NCT03219320 (GlobeNewswire) 人工标引	临床2期	糖尿病周围神经病变	300	NYX-2925	願淵廠觸構願窪鹽鏇遞(鹽鹽鹹膚繭襯糧觸遞網) = 衊鹽襯顧鹹鹹膚繭選餘範夢製範蓋壓願積餘齋 (醖蓋獵構構餘蓋鑰繭衊 )	不佳	2019-01-16
				Placebo	願淵廠觸構願窪鹽鏇遞(鹽鹽鹹膚繭襯糧觸遞網) = 鏇窪製艱顧襯窪壓遞顧範夢製範蓋壓願積餘齋 (醖蓋獵構構餘蓋鑰繭衊 )